UNION CITY, Calif. - (Business Wire)
Questcor Pharmaceuticals, Inc. (AMEX:QSC) announced today that it will release financial results for the first quarter of fiscal 2008 ended March 31, 2008, before the market opens on Wednesday, April 30, 2008. The company will host a conference call to discuss these results on Wednesday, April 30, 2008 at 11:00 a.m. ET. During this call the company will discuss it first quarter 2008 results. Don Bailey, President and Chief Executive Officer and Steve Cartt, Executive Vice President, Corporate Development will host the call.
To participate in the live call by telephone, please dial (800) 257-7087 from the U.S. or (303) 262-2140 from outside the U.S. Please use conference ID number 11113031#. Participants are asked to call the above numbers 5-10 minutes prior to the starting time. The call will also be webcast live at www.questcor.com. An audio replay of the call will be available for 7 days following the call at (800) 405-2236 for U.S. callers or (303) 590-3000 for those calling outside the U.S. The password required to access the replay is 11113031#. An archived webcast will also be available at www.questcor.com for 90 days.
About Questcor - Questcor Pharmaceuticals, Inc. is a pharmaceutical company that owns two commercial products, H.P. Acthar ® Gel (“Acthar”) and Doral ® , and is developing new medications using strategies that generally require lower capital investment when compared to traditional development programs. Acthar (repository corticotropin injection) is an injectable drug that is approved for the treatment of certain disorders with an inflammatory component, including the treatment of exacerbations associated with multiple sclerosis (“MS”). In addition, Acthar is not indicated for, but is used in treating patients with infantile spasms (“IS”), a rare form of refractory childhood epilepsy, and opsoclonus myoclonus syndrome, a rare autoimmune-related childhood neurological disorder. Doral is indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. The Company is also developing new medications, including QSC-001, a unique orally disintegrating tablet formulation of hydrocodone bitartrate and acetaminophen for the treatment of moderate to moderately severe pain. For more information, please visit www.questcor.com.
Questcor Pharmaceuticals, Inc.
Don Bailey, 510-400-0700
Steve Cartt, 510-400-0700
IR2@Questcor.com
or
EVC Group, Inc.
Doug Sherk, 415-896-6820 (Investors)
Matthew Selinger, 415-896-6817(Investors)
Steve DiMattia, 646-201-5445 (Media)
